À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ磨×ܲ¿£º¶«¾©£¬Ê×ϯִÐй٣ºÄÚÌÙÇç·ò£¬¡°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡±£©½üÈÕÐû²¼£¬ÒÑÔÚÈÕ±¾»ñµÃEZH2ÒÖÖƼÁ¡°Tazverik?200 mgƬ¼Á¡±£¨ÇâäåËáÌ©Ôó˾Ëû£©µÄÉú²úºÍÉÏÊÐÐí¿É£¬ÓÃÓÚÖÎÁÆEZH2»ùÒòÍ»±äÑôÐԵĸ´·¢»òÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö£¨½öÔڳ߶ÈÖÎÁƲ»ÊÊÓÃʱʹÓã©¡£
±¾´Î»ñÅú»ùÓÚÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚÈÕ±¾¿ªÕ¹µÄÒ»Ïî¶àÖÐÐÄ¡¢¿ª·ÅÐÔ¡¢µ¥±ÛIIÆÚÁÙ´²ÊÔÑ飨Ñо¿206£©1ºÍEpizyme, Inc.£¨×ܲ¿£ºÃÀ¹úÂíÈøÖîÈûÖÝ£©ÔÚÈÕ±¾¾³Í⿪չµÄÆäËûÑо¿2µÄ½á¹û¡£ Ñо¿206Èë×éÁËEZH2»ùÒòÍ»±äÑôÐԵĸ´·¢»òÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö»¼Õß¡£¸ÃÑо¿µÄÖ÷ÒªÖÕµãΪ¿Í¹Û»º½âÂÊ£¨ORR£©£¬´ÎÒªÖÕµã°üÂÞÄþ¾²ÐÔ¡£¸ÃÑо¿µ½´ïÁËÖ÷ÒªÖÕµãÄ¿±ê£¬²¢Áè¼ÝÁËÔ¤ÏÈÖ¸¶¨µÄÖ×Áö»º½âãÐÖµ£¬¾ßÓÐͳ¼ÆѧÒâÒ壺¾¶ÀÁ¢Éó²éµÄÖ¸±ê£¬¼´EZH2Í»±äÑôÐԵĸ´·¢»òÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö»¼Õߣ¨n=17£©µÄORRΪ76.5%£¨90%ÖÃÐÅÇø¼ä£¨CI£©£º53.9 – 91.5£©¡£¸ÃÑо¿ÖÐÊӲ쵽µÄÖÎÁÆÖзºÆðµÄ²»Á¼Ê¼þ£¨·¢ÉúÂÊ¡Ý25%£©ÎªÎ¶¾õÕÏ°£¨52.9%£©¡¢±ÇÑÊÑ×£¨35.3%£©¡¢ÁÜ°Íϸ°û¼õÉÙÖ¢£¨29.4%£©ºÍѪ¼¡ËáÁ×ËἤøÉý¸ß£¨29.4%£©¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«Æ¾¾ÝMHLW¹æ¶¨µÄÅú×¼Ìõ¼þ£¬¶ÔËùÓнÓÊÜ¡°Tazverik¡±ÖÎÁƵĻ¼Õß¿ªÕ¹Ò»ÏîÉÏÊкóÌØÊâʹÓýá¹ûÊӲ죨ËùÓв¡Àý¼à²â£©£¬Ö±µ½µ½´ïÔ¤¶¨µÄ»¼ÕßÊýÁ¿¡£
¡°Tazverik¡±ÊDZí¹ÛÒÅ´«Ã¸EZH2µÄÒ»ÖÖÐÂÐÍС·Ö×ÓÒÖÖƼÁ£¬Í¨¹ýEpizymeµÄרÀû²úÎïƽ̨´´½¨¡£¡°Tazverik¡±ÊÇÒ»´óÀà±í¹ÛÒÅ´«Ïà¹ØÂÑ°×ÖеÄ×éÂÑ°×¼×»ùתÒÆø֮һ£¬Í¨¹ýÌØÒìÐÔ°ÐÏò´Ù½ø°©Ö¢½øÕ¹µÄEZH2£¬µ÷Öΰ©Ö¢Ïà¹Ø»ùÒòµÄ±í´ï¡¢ÒÖÖÆ°©Ï¸°ûµÄÉú³¤3¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÂôÁ¦¸ÃÒ©ÎïÔÚÈÕ±¾µÄ¿ª·¢ºÍÏúÊÛ£¬¶øEpizymeÂôÁ¦ÈÕ±¾ÒÔÍâµÄËùÓеØÓò¡£ÔÚÃÀ¹ú£¬¡°Tazverik¡±ÓÚ2020Äê1Ô»ñµÃ¼ÓËÙÅú×¼ÓÃÓÚÖÎÁÆÉÏƤÑùÈâÁö£¬2020Äê6Ô»ñµÃ¼ÓËÙÅú×¼ÓÃÓÚÖÎÁÆÂËÅÝÐÔÁÜ°ÍÁö£¨±àÕß×¢1£©¡£
ÂËÅÝÐÔÁÜ°ÍÁöÊÇÒ»Öֵͼ¶±ðBϸ°ûÁÜ°ÍÁö£¬Õ¼·Ç»ôÆæ½ðÁÜ°ÍÁöµÄ10-20%¡£ÂËÅÝÐÔÁÜ°ÍÁöͨ³£Éú³¤»ºÂý£¬¶øÇÒ¶Ô»¯ÁÆÃô¸Ð¡£È»¶ø£¬ÒòΪ¸Ã¼²²¡Öظ´¸´·¢£¬ÂËÅÝÐÔÁÜ°ÍÁöÈÔÄÑÒÔÖÎÓú£¬ÐèÒªÑз¢ÐµÄÖÎÁƼÆı¡£¾Ý±¨µÀ£¬7%ÖÁ27%µÄÂËÅÝÐÔÁÜ°ÍÁö»¼Õß°éÓÐEZH2»ùÒò¹¦Ð§»ñµÃÐÔÍ»±ä4,5£¬ÔÚÈÕ±¾Ô¼ÓÐ600ÖÁ2400ÃûÂËÅÝÐÔÁÜ°ÍÁö»¼Õß·¢ÉúEZH2Í»±ä¡£Roche Diagnostics K.K.£¨×ܲ¿£º¶«¾©£©µÄEZH2»ùÒòÍ»±äÅãͬÕï¶Ï¼ì²â¡°cobas?EZH2Í»±ä¼ì²â¡±ÓÚ2021Äê5Ô»ñµÃÅú×¼¡£
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö¼ÔÚÌṩ¡°Tazverik¡±×÷ΪEZH2»ùÒòÍ»±äÑôÐÔµÄÂËÅÝÐÔÁÜ°ÍÁöµÄÐÂÖÎÁÆÑ¡Ôñ£¬Á¬ÐøÂú×ã°©Ö¢»¼Õß¼°Æä¼ÒÊôºÍÒ½ÎñÈËÔ±µÄ¶àÑù»¯ÐèÇó£¬ÎªÌáÉýÆ丣ìí×ö³öТ¾´¡£
ýÌå×Éѯ£º
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉç
¹«¹²¹Øϵ²¿
+81-(0)3-3817-5120
[±àÕß×¢]
1.¹ØÓÚ¡°Tazverik 200 mgƬ¼Á¡±£¨ÇâäåËáÌ©Ôó˾Ëû£¬Ñз¢´úÂ룺E7438£¬Epizyme, Inc.µÄÑз¢´úÂ룺EPZ-6438£©
¡°Tazverik¡±ÊÇÒ»ÖÖ°ÐÏòEZH2µÄÐÂÐÍ¿Ú·þС·Ö×ÓÒÖÖƼÁ¡£Æ¾¾ÝË«·½2011Äê3Ô¸濢µÄÕë¶ÔEZH2µÄÑз¢ºÍÏúÊÛºÏ×÷ÐÒ飬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍEpizymeÀûÓÃEpizymeµÄרÀû²úÎïƽ̨½øÐÐÁËÁªºÏÑз¢¡£¸ÃÒ©ÎïÑ¡ÔñÐÔµØÒÖÖÆEZH2£¬EZH2ÓëS-ÏÙÜÕ¼×Áò°±Ëᣨ¼×»ù¹©Ì壩¾ºÕù£¬´Ó¶øÒÖÖÆH3K27µÄ¼×»ù»¯¡£ÓÉÓÚ2015Äê3ÔÂÁ½¼Ò¹«Ë¾µÄºÏ×÷ÐÒé·¢Éú±ä»»£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÂôÁ¦¸ÃÒ©ÎïÔÚÈÕ±¾µÄ¿ª·¢ºÍÏúÊÛ£¬¶øEpizymeÂôÁ¦ÈÕ±¾ÒÔÍâµÄËùÓеØÓò¡£
ÔÚÈÕ±¾áª¸·ÏصĴ¨µº¹¤ÒµÔ°£¬Ò²¾ÍÊDZ¾Æ·ÔÚÈÕ±¾µÄÉú²úËùÔÚ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÀֳɿª·¢³ö´´ÐµÄÖÆÒ©Éú²ú¼¼Êõ£¬¼´ËùνµÄ¡°Á¬ÐøÉú²ú¡±£¬²¢½«ÆäÓ¦ÓÃÓÚʵ¼ÊÉú²ú¡£Á¬ÐøÉú²úͨ¹ý¼¯³ÉÖÆÔì×Ô¶¯»¯ºÍʵʱÖÊÁ¿¼à²â¼¼Êõ£¬ÓÐÖúÓÚÒ©Æ·µÄÖÊÁ¿¸ïкÍÎȶ¨¹©Ó¦¡£´ËÍ⣬Á¬ÐøÉú²ú×÷ΪһÖÖеÄÒ©Æ·Éú²úÒªÁ죬Äܹ»Ìá¸ßЧÂÊ¡¢½ÚÊ¡¿Õ¼äºÍÄÜÔ´£¬Í¬Ê±¼õÉÙ»·¾³¸ººÉ£¬ÊÇÒ»ÏÊܹØ×¢µÄ¼¼Êõ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÊÇ×îÔç½ÓÄÉÁ¬ÐøÉú²úϵͳ£¨CTS-MiGRA£©µÄ¹«Ë¾Ö®Ò»£¬²¢½«¸Ã¼¼ÊõÓ¦ÓÃÓÚ±¾Æ·µÄÉú²ú¡£
±¾Æ·ÓÚ2020Äê1ÔÂÔÚÃÀ¹ú»ñµÃ¼ÓËÙÅú×¼£¬ÓÃÓÚÖÎÁÆ¡°²»ÊʺϽÓÊܸùÖÎÐÔÇгýµÄתÒÆÐÔ»ò¾Ö²¿ÍíÆÚÉÏƤÑùÈâÁöµÄ³ÉÈ˺͡Ý16ËêµÄ¶ùͯ»¼Õß¡±¡£´ËÍ⣬ͬÄê6Ô£¬±¾Æ·»ñµÃ¼ÓËÙÅú×¼£¬ÓÃÓÚÖÎÁÆ¡°¼ÈÍù½ÓÊܹýÖÁÉÙ2ÖÖÖÎÁÆ·½°¸ÇÒEZH2Í»±äÑôÐÔ£¨¾FDAÅú×¼µÄ¼ì²âÒªÁì¼ì²â£©µÄ³ÉÈ˸´·¢/ÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö¡±£¬ÒÔ¼°¡°Ã»ÓÐÁîÈËÂúÒâµÄÌæ´úÖÎÁÆÑ¡ÔñµÄ³ÉÈ˸´·¢/ÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö¡±¡£
?
2.¹ØÓÚ±í¹ÛÒÅ´«Ñ§
±í¹ÛÒÅ´«Ñ§ÊÇÑо¿»ùÒò¹¦Ð§»ñµÃÐÔ¼¤»î/ʧ»î»úÖƵĿÆѧ·ÖÖ§£¬Ñо¿ÔÚDNA¼î»ùÐòÁв»·¢Éú¸Ä±äµÄÇé¿öÏ£¬»ùÒò¹¦Ð§ÈçºÎͨ¹ýϸ°ûÆÆÁѽøÐÐÒÅ´«¡£µ¼Ö»ùÒò±í´ïµ÷¿ØµÄÐÞÊÎʵÀý°üÂÞDNAµÄ¼×»ù»¯ºÍ×éÂÑ°×µÄÐÞÊΣ¨¼×»ù»¯¡¢ÒÒõ£»¯¡¢Á×ËữµÈ£©¡£
3.¹ØÓÚEZH2
EZH2ÊÇÒ»´óÀà±í¹ÛÒÅ´«Ïà¹ØÂÑ°×ÖеÄ×éÂÑ°×¼×»ùתÒÆø֮һ£¬ÌØÒìÐÔ´ß»¯×éÂÑ°×H3ÔÚÀµ°±Ëá27£¨H3K27£©µÄ¼×»ù»¯£¬´Ó¶ø¿ØÖÆÖÖÖÖ»ùÒòµÄ±í´ï¡£Ñо¿±íÃ÷£¬ÓÉEZH2¹¦Ð§»ñµÃÐÔÍ»±ä¡¢¹ý±í´ï»òEZH2ÒÖÖÆÒò×ӵĹ¦Ð§ÕÏ°ÒýÆðµÄH3K27¼×»ù»¯Ôö¼ÓÔÚÖ°©¹ý³ÌÖÐÆðµ½ÖØÒª×÷Óá£
1 Shinya Rai£¬et al. TazemetostatÖÎÁÆÈÕ±¾¸´·¢»òÄÑÖÎÐÔEZH2Í»±äÑôÐÔµÄBϸ°û·Ç»ôÆæ½ðÁÜ°ÍÁö»¼ÕßµÄIIÆÚÑо¿¡£2021ÄêAACR»áÒ飬CT176.
2 Franck Morschhauser£¬et al. TazemetostatÖÎÁƸ´·¢»òÄÑÖÎÐÔÂËÅÝÐÔÁÜ°ÍÁö»¼ÕߣºÒ»Ï·Å±êÇ©¡¢µ¥±Û¡¢¶àÖÐÐÄ¡¢IIÆÚÊÔÑé¡£¡¶ÁøÒ¶µ¶Ö×Áöѧ¡·£¬2020Äê11Ô£»21(11):1433-1442¡£
3 Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, et al. EPZ-6438Ñ¡ÔñÐÔÒÖÖÆEZH2¿Éµ¼Ö¶ÔEZH2Í»±äÐÍ·Ç»ôÆæ½ðÁÜ°ÍÁöµÄǿЧ¿¹Ö×Áö»îÐÔ¡£¡¶·Ö×Ó°©Ö¢ÖÎÁÆѧ¡·£¬2014Äê4Ô£»13(4):842-854¡£
4 Csaba B?d?r£¬et al. EZH2Í»±äƵ·±£¬´ú±íÂËÅÝÐÔÁÜ°ÍÁöµÄÔçÆÚʼþ¡£¡¶ÑªÒºÑ§¡·£¬2013Äê10Ô£»122(18), 3165-3168¡£
5 Ryan D. Morin, et al. Éú·¢ÖÐÐÄÆðÔ´µÄÂËÅÝÐÔºÍÃÖÂþÐÔ´óBϸ°ûÁÜ°ÍÁöµÄÌåϸ°ûEZH2£¨Y641£©Í»±ä¡£¡¶×ÔÈ»ÒÅ´«Ñ§¡·£¬2010Äê2Ô£»42(2): 181-185¡£
Copyright(c) 2011 Eisai China lnc.All Rights Reserved. »¦ICP±¸11005394ºÅ-1 »¦¹«Íø°²±¸31010602001439ºÅ
021-62881220
? Ò©´ú´æ°¸ÐÅÏ¢²éѯ ? ÒÑÉÏÊÐÌæÆÕÈðͪ½ºÄÒ¸õÏÞÁ¿¼ìÑé³ÂËß¹«Ê¾ËµÃ÷
? Ö´·¨Í¨¸æ ? Òþ˽Õþ²ß ? ¿ÉÓÃÐÔ
±¾ÍøվʹÓÃCookiesÒÔʹÄú»ñµÃ×î¼ÑµÄÌåÑ顣ΪÁ˼ÌÐøä¯ÀÀ±¾ÍøÕ¾£¬ÄúÐèͬÒâÎÒÃǶÔCookiesµÄʹÓá£ÏëÒªÁ˽â¸ü¶àÓйØÓÚCookiesµÄÐÅÏ¢£¬»ò²»Ï£Íûµ±ÄúʹÓÃÍøվʱ·ºÆðcookies£¬ÇëÔĶÁÎÒÃǵÄCookiesÉùÃ÷£¡
ÎÒÃÇ¿ÉÄÜ»áÒªÇóÔÚÄúµÄÉ豸ÉÏÉèÖÃCookie¡£ÎÒÃÇʹÓÃcookiesÀ´¸æËßÎÒÃÇÄúºÎʱ·ÃÎÊÎÒÃǵÄÍøÕ¾£¬ÄúÈçºÎÓëÎÒÃÇ»¥¶¯£¬¸»ºñÄúµÄÓû§ÌåÑ飬ÒÔ¼°ÈçºÎ¶¨ÖÆÄúÓëÎÒÃÇÍøÕ¾µÄ¹Øϵ¡£
µã»÷²îÒìµÄÀà±ð±êÌâÒÔÁ˽â¸ü¶àÐÅÏ¢¡£ÄãÒ²¿ÉÒԸıäÄãµÄһЩƫºÃ¡£Çë×¢Ò⣬×èֹijЩÀàÐ͵ÄCookie¿ÉÄÜ»áÓ°ÏìÄúÔÚÎÒÃÇÍøÕ¾ÉϵÄÌåÑéÒÔ¼°ÎÒÃÇËùÄÜÌṩµÄ·þÎñ¡£
ÕâЩ Cookie ÊÇΪÄúÌṩͨ¹ýÎÒÃǵÄÍøÕ¾ÌṩµÄ·þÎñ²¢Ê¹ÓÃÆäijЩ¹¦Ð§µÄÑϸñÐëÒªÌõ¼þ¡£
ÕâЩcookies¾ø¶ÔÓÐÐëҪΪÄúÌṩͨ¹ýÎÒÃÇÍøÕ¾ÌṩµÄ·þÎñ²¢Ê¹ÓÃÆäÖеÄһЩ¹¦Ð§¡£
ÓÉÓÚÕâЩcookies¾ø¶ÔÊǽ»¸¶ÍøÕ¾Ëù±ØÐëµÄ£¬Òò´ËÄú²»ÄÜÔÚ²»Ó°ÏìÎÒÃÇÍøÕ¾¹¦Ð§µÄÇé¿öϾܾøËûÃÇ¡£Äú¿ÉÒÔͨ¹ý¸ü¸Ää¯ÀÀÆ÷ÉèÖÃÀ´×èÖ¹»òɾ³ýËüÃÇ£¬²¢Ç¿ÖÆ×èÖ¹±¾ÍøÕ¾ÉϵÄËùÓÐCookie¡£
Èç¹ûÄúÏë¾Ü¾ø±ý¸É£¬µ«ÎªÁËÖÆÖ¹ÔÙ´ÎÒªÇóÄú£¬ÎÒÃÇÍêÈ«×ðÖØ£¬ÇëÔÊÐíÎÒÃÇ´æ´¢±ý¸É¡£Äú¿ÉÒÔËæʱѡÔñÍ˳ö»òÑ¡ÔñÆäËû Cookie ÒÔ»ñµÃ¸üºÃµÄÌåÑé¡£Èç¹ûÄú¾Ü¾ø Cookie£¬ÎÒÃǽ«É¾³ýÎÒÃÇÓòÃûÖеÄËùÓÐÉèÖà Cookie¡£
ÎÒÃÇΪÄúÌṩÄúËù´æ´¢µÄ Cookie ÁÐ±í£¬ÒÔ±ãÄú¼ì²ìÎÒÃÇ´æ´¢µÄÄÚÈÝ¡£³öÓÚÄþ¾²ÔÒò£¬ÎÒÃÇÎÞ·¨ÏÔʾ»òÐÞ¸ÄÀ´×ÔÆäËûÓòµÄ Cookie¡£Äú¿ÉÒÔÔÚä¯ÀÀÆ÷Äþ¾²ÉèÖÃÖмì²éÕâЩÄÚÈÝ¡£
ÎÒÃÇ»¹Ê¹ÓòîÒìµÄÍⲿ·þÎñ£¬ÈçGoogle Webfonts¡¢Google MapsºÍÍⲿÊÓƵÌṩÉÌ¡£ ÓÉÓÚÕâЩÌṩÉÌ¿ÉÄÜ»áÊÕ¼¯ÄúµÄ IP µØÖ·µÈ¸öÈËÊý¾Ý£¬Òò´ËÎÒÃÇÔÊÐíÄúÔÚ´Ë´¦×èÖ¹ÕâЩÊý¾Ý¡£Çë×¢Ò⣬Õâ¿ÉÄÜ»áÑÏÖؽµµÍÎÒÃÇÍøÕ¾µÄ¹¦Ð§ºÍÍâ¹Û¡£ ¸Ä±ä3D¿Õ¼äÖÐͼ²ãµÄ͸ÊÓ¡£
¹È¸èÍøÂç×ÖÌåÉèÖãº
¹È¸èµØͼÉèÖÃ
Google reCaptchaÉèÖãº
Vimeo ºÍ Youtube ÊÓƵǶÈ룺
Äú¿ÉÒÔÔÚÎÒÃǵÄÒþ˽Õþ²ßÒ³ÃæÏêϸÁ˽âÎÒÃǵÄCookieºÍÒþ˽ÉèÖá£